DXCM - CIK 0001093557
The table below shows DEXCOM INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $525.60M | $183.80M | $209.20M | $155.40M | $71.00M | $27.80M |
| Capital expenditure | $76.60M | $87.00M | $56.90M | $74.70M | $101.60M | $99.70M |
| Investing cash flow | -$298.50M | $100.20M | $74.80M | -$186.70M | -$411.80M | -$112.20M |
| Dividends paid | - | - | - | - | - |
DEXCOM INC reported operating cash flow of $1.44B for fiscal year 2025. That is up 45.6% from $989.50M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $56.20M (FY 2016) to $1.44B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$25.00M | $12.50M | $4.70M | $11.20M | $5.30M | $800.00K |